Retirement of Guidelines

No authors listed

No authors listed. Neurology. 2025.

. 2025 May 13;104(9):e213572.

doi: 10.1212/WNL.0000000000213572. Epub 2025 Apr 14.

No abstract available

Retraction of

Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy [RETIRED]: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Gloss D, Moxley RT 3rd, Ashwal S, Oskoui M. Gloss D, et al. Neurology. 2016 Feb 2;86(5):465-72. doi: 10.1212/WNL.0000000000002337. Neurology. 2016. Retraction in: Neurology. 2025 May 13;104(9):e213572. doi: 10.1212/WNL.0000000000213572. PMID: 26833937 Free PMC article. Retracted. Review.
Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus [RETIRED]: A Report of the AAN Guidelines Subcommittee.
Day GS, Scarmeas N, Dubinsky R, Coerver K, Mostacero A, West B, Wessels SR, Armstrong MJ. Day GS, et al. Neurology. 2022 Apr 12;98(15):619-631. doi: 10.1212/WNL.0000000000200176. Epub 2022 Feb 23. Neurology. 2022. Retraction in: Neurology. 2025 May 13;104(9):e213572. doi: 10.1212/WNL.0000000000213572. PMID: 35197360 Free PMC article. Retracted.

1. American Academy of Neurology. Practice Guidelines. aan.com/practice/guidelines
1. Day GS, Scarmeas N, Dubinsky R, et al. Aducanumab use in symptomatic Alzheimer disease evidence in focus: a report of the AAN Guidelines Subcommittee. Neurology. 2022;98(15):619-631. doi: 10.1212/WNL.0000000000200176 - DOI - PMC - PubMed
1. Gloss D, Moxley RT, Ashwal S, Oskoui M. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;85(5):465-472. doi: 10.1212/WNL.0000000000002337 - DOI - PubMed